An Open-label, Single-Arm Pilot Study Investigating the Efficacy and Safety of Apremilast for the Treatment of Moderate to Severe Chronic Hand Dermatitis
Phase of Trial: Phase IV
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs Apremilast (Primary)
- Indications Dermatitis
- Focus Therapeutic Use
- 21 Nov 2019 Status changed from not yet recruiting to discontinued.
- 17 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Feb 2019.
- 22 Nov 2018 New trial record